home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Understanding HIV Drug Resistance

  April, 27 2004 9:48
your information resource in human molecular genetics
HIV is notorious for the ability to escape many drugs designed to stop its action. However, these viruses do not readily develop resistance to tenofovir, a drug that inhibits a viral protein called reverse transcriptase (RT) that is crucial for replicating the viral genome. A study in the May issue of Nature Structural & Molecular Biology reports two related structures of RT with bound tenofovir. The results explain the unusually low resistance of HIV to tenofovir.

HIV RT synthesizes a single-stranded DNA based on the viral genome RNA template. Similar to other drugs in its class, tenofovir resembles one of the four building blocks of DNA and can be incorporated into the growing DNA chain by HIV RT. After incorporation, these inhibitors stop further chain growth, therefore preventing the production of new viral genome. However, HIV resistance to tenofovir develops much slower than that to other inhibitors in this class, such as AZT.

To understand the basis for this low resistance, Eddy Arnold and colleagues have determined the structures of HIV RT bound to RNA-DNA template-primer and tenofovir. The structures show that mutations in RT that could reduce tenofovir incorporation would also substantially diminish the natural function of the enzyme. Furthermore, incorporated tenofovir can escape 'correction' activity of RT by moving out of the active site of the enzyme with the growing chain. The structures thus provide insights into the mechanisms of HIV drug resistance.

Author contact:

Eddy Arnold
Rutgers University
Piscataway, NJ
Tel: +1 732 235 5323
E-mail: arnold@cabm.rutgers.edu

Also available online.

(C) Nature Structural & Molecular Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.